CHM Insider Trading

Insider Ownership Percentage: 24.22%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Chimeric Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Chimeric Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chimeric Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 03/11/2021 11:04 AM ET

This chart shows the closing price history over time for CHM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Get all the details here >>>

Chimeric Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/12/2023George MatchamInsiderIssued1,086,956A$0.05A$49,999.98
12/12/2022Jennifer ChowInsiderIssued3,300,325A$0.09A$293,728.93
11/18/2022Jennifer ChowInsiderIssued17,222,368A$0.09A$1,498,346.02
6/29/2022Leslie (Mi Ok) ChongInsiderBuy30,000A$0.10A$2,940.00
3/25/2022Leslie (Mi Ok) ChongInsiderIssued3,905A$0.15A$585.75
8/4/2021George MatchamInsiderBuy500,000A$0.33A$166,000.00
3/8/2021Cynthia ElkinsInsiderBuy24,800A$0.32A$7,886.40
See Full Table
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Here's what you need to do now to profit.

SEC Filings (Institutional Ownership Changes) for Chimeric Therapeutics (ASX:CHM)

2.10% of Chimeric Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Read More on Chimeric Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Who are the company insiders with the largest holdings of Chimeric Therapeutics?

Chimeric Therapeutics' top insider shareholders include:
  1. George Matcham (Insider)
  2. Jennifer Chow (Insider)
  3. Leslie (Mi Ok) Chong (Insider)
Learn More about top insider investors at Chimeric Therapeutics.